Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer

19 Nov 2019

Abstract excerpt

Abstract Purpose: DNA mismatch repair defects (MMRd) and tumor hypermutation are rare and under-characterized in metastatic prostate cancer (mPC). Furthermore, because hypermutated MMRd prostate cancers can respond to immune checkpoint inhibitors, there is an urgent need for practical detection tools. Experimental Design: We analyzed plasma cell-free DNA-targeted sequencing data from 433 patients with mPC with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Genetic factors in colorectal cancer
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31744831
DOI: 10.1158/1078-0432.ccr-19-1623

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate CancerPMID 31744831Read ↗

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesisSemantic proximity Read ↗

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesisSemantic proximity Read ↗

Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.Semantic proximity Read ↗

Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.Semantic proximity Read ↗

Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.Semantic proximity Read ↗

Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate CancerSemantic proximity Read ↗

Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate.Semantic proximity Read ↗

AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients.Semantic proximity Read ↗

Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretationSemantic proximity Read ↗

Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.Semantic proximity Read ↗

Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound.Semantic proximity Read ↗

Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.